MedTrace Logo

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

NCT03909971 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2025-11-05

Study results available
· View outcomes & findings →

Summary

A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer patients in China

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Lorlatinib

ALK inhibitor-treated ALK-positive NSCL treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-28
Primary Completion
2020-08-10
Completion
2024-10-21
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03909971 on ClinicalTrials.gov